Brown-Forman Corporation (BF-A): what the price requires

The current priced-in claim for Brown-Forman Corporation (BF-A) is temporarily suppressed because the live engine record is unavailable. The dated report remains a snapshot, not a current market read.

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/BF-A

Headline

FieldValue
TickerBF-A
CompanyBrown-Forman Corporation
Current price$26.63/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed11.6%
Operating margin today29.3%
Margin compression implied-17.7pp
Multiple paid11x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7.7% cost of capital with 4% terminal growth over a 5-year stage.

Reconcile: at the x-ray's 9.3% required return this reads ~-0.8%/yr; the models below use their own rates.

How unusual the bet is: within-range

ReferenceValue
vs own history-0.76σ
cohort percentile (of 69 peers)12
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple; earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.35x4expensive
Earnings1.68x4expensive
Relative1.05x3expensive
Growth1.37x4expensive

Families that justify the price: Relative Families that call it expensive: Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.6%); the inversion above states its own rate.

Per-Model Detail (n=15)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$21.881.22xyesFCF base $0.9B, growth 1% (input: historical growth), terminal g 0.6%, WACC 7.6%, 5yr projection
DCF Exit MultipleGrowth$26.561.00xyesExit EV/EBITDA: 12.6x / 14.6x / 16.6x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$29.730.90xyesP/E 22x (static sector reference · 2026-04), scenarios: 18.7x / 22.0x / 25.3x (bear / base = reference held flat / bull), EV/EBITDA 14x
Simple DDMGrowthno
Two-Stage DDMGrowth$5.035.29xyesStage 1: -22% for 5yr, Stage 2: 3.5% perpetual
Simple Excess ReturnAsset$16.701.59xyesBV/sh $8.69, ROE (TTM) 17.8%, ke 9.3%
Two-Stage Excess ReturnAsset$22.861.16xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$17.491.52xyesRev $5.1B, growth 1% (input: historical growth; tapered), Terminal P/S: 2.1x / 2.4x / 2.8x (bear / base = today's held flat / bull, cap 8x)
Growth-Adjusted P/ERelativeno
Margin TrajectoryGrowthno
Earnings Power ValueEarnings$20.021.33xyesNormalized EBIT (5y avg op income, one-time charges added back) $1.19B × (1−24%) / WACC 7.6% → EPV (no growth)
Residual IncomeAsset$22.781.17xyesBV $8.69 + 5yr PV of (ROE (TTM) 17.8% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$17.291.54xyes√(22.5 × EPS $1.53 × BVPS $8.69) — Graham's conservative floor
EV/EBITDA RelativeRelative$25.361.05xyesEBITDA $1.02B × sector EV/EBITDA 14.0x
FCF YieldEarnings$15.271.74xyesFCF $893.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$14.521.83xyesSBC-adj FCF $0.86B (FCF $0.89B − SBC $0.03B) capitalized at Kₑ
Ben Graham FormulaEarnings$1.2820.80xyesEPS $1.53 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset$1.2621.13xyesBV $8.69 × (ROIC 1.1% / WACC 7.6%) (excluded from median)
P/Sales SectorRelative$21.961.21xyesRevenue $5.08B × sector P/S 2.0x
PEG Fair ValueRelativeno
Earnings YieldEarnings$16.541.61xyesEPS $1.53 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelativeno
Clinical Phase NPVGrowthno
MertonAssetno
V5 Mechanicalno

Solvency

FieldValue
Net debt$2.2b
Net debt / NOPAT (after-tax)2.43x
Net debt / operating income (pre-tax)1.85x
Interest coverage11.0x
Share count CAGR (buyback)-0.9%
Burning cashno

Bullet Takeaways

Bull Case

The counterintuitive fact about Brown-Forman right now is that the business barely moved while the stock and the reported numbers cratered. For fiscal 2026, reported net sales fell 1% to $3.9 billion but were flat on an organic basis, and reported operating income dropped 10% to $1.0 billion yet declined only 2% organically. The gap between reported and organic is the whole bull case in one line: the damage came from foreign-exchange, divestitures, and one-time charges, not from the underlying brands losing their grip on the consumer. A 200-year-old portfolio led by Jack Daniel's does not lose its franchise in a year; it gets repriced by headlines.

The brand engine still works where trade politics let it. The 10-K points to Brazil net sales up 12% on the volumetric growth of the Jack Daniel's family of brands, reflecting expanded distribution, increased consumer-led demand, and to innovation within the Jack Daniel's family that has contributed to our growth in the last two fiscal years, from flavored extensions to ready-to-drink formats. These are the levers a premium spirits company pulls to grow without discounting, and they are still pulling in markets not caught in the tariff crossfire. Premium spirits remain a structurally attractive category: brand loyalty is durable, pricing power is real, and the assets are irreplaceable.

Net debt of about $2.2 billion sits at roughly two times operating income with interest coverage near 9.7 times, comfortable for a consumer-staples business, and the share count keeps drifting down through buybacks. At about 11 times operating income, the price sits below what even a 5%-a-year decline in operating profit would warrant, which is to say the market is pricing in deterioration that the organic numbers do not yet show. For a company with this brand equity, a price that already assumes ongoing decline is the setup the patient buyer looks for.

Bear Case

The bear case is a sector caught between a cyclical hangover and a political shock, and Brown-Forman sits in the middle of both. Spirits demand has been working off a pandemic-era bulge: distributors overstocked, consumers pulled forward purchases, and the industry has spent two years destocking back to normal. Layered on top is the acute damage from trade politics. The Canadian boycott of American alcohol, spurred by U.S. tariff policy, cut Canada sales by 62% in a quarter, and the EU and Canadian provinces have begun removing American spirits from shelves. Jack Daniel's is one of America's most visible whiskey exports, which makes it a target precisely because it is iconic. This is demand destruction the company cannot control and cannot quickly replace.

The reported earnings show how hard those forces hit. Full-year reported operating income fell 10% to $1.0 billion and diluted EPS dropped 17% to $1.53, with the fourth quarter brutal: operating income down 53% and EPS down 62% to $0.12, weighed by impairment and inventory charges. Even allowing for one-time items, the trajectory is down, and the question a holder must face is whether peak spirits demand and peak Jack Daniel's distribution are behind the company rather than ahead of it. Operating margin has compressed from the high-20s and 30s the company once earned to under 20% on a trailing basis, and a margin that has fallen this far does not always snap back on schedule.

The valuation looks cheap, but the earnings-power lens says otherwise, and the reason matters. At 11 times operating income the multiple is low, yet the earnings-power method, which values the company on its recent average profitability, reads the price as expensive because that average is now falling. If the tariff disruption persists, if GLP-1 weight-loss drugs durably dent alcohol consumption, or if the destocking gives way to genuine demand softness rather than a one-time reset, then the "cheap" multiple is cheap against earnings that keep shrinking. A low multiple on a declining base is a value trap, not a bargain, and the bear's job is to ask whether the decline is temporary or the new normal.

Valuation

The price tells a story of expected decline. At about 11 times company-wide operating income, Brown-Forman trades below what even a 5%-a-year drop in operating profit would justify, which means the market is already pricing in continued deterioration. For a premium spirits franchise that has compounded for generations, that is an unusual posture, and it reflects the tariff shock and the spirits-industry destocking rather than a verdict on the brands themselves.

The methods disagree in an instructive way. The relative-multiple family justifies the price, comparing Brown-Forman to other consumer-staples and spirits names where the stock now trades at a discount to its own past richness. The earnings-power lens, by contrast, reads the price as expensive, not because 11 times is high but because the recent average operating income the method capitalizes is falling. That tension is the crux: the price is cheap against a stable earnings base and full against a declining one, and which is right depends entirely on whether the current margin compression reverses. The asset and growth lenses sit roughly at the price, leaving the read genuinely balanced.

Solvency removes the downside-disaster scenario. Net debt of about $2.2 billion at roughly two times operating income, with interest coverage near 9.7 times, is a conservative balance sheet for a consumer-staples company, and the steady buyback keeps shrinking the share count. The dividend, long a hallmark of the stock, is well covered even at the depressed earnings level, though the tariff-battered results have put its growth rate under more scrutiny than usual. The downside here is not financial; it is the risk that the earnings base settles permanently lower. A buyer at this price is betting the organic stability, flat full-year organic net sales, proves more durable than the reported decline, and that the brands re-rate once the trade disruption clears.

Catalysts

Brown-Forman closed fiscal 2026, ended April 30, with results that split sharply between reported and organic. Full-year reported net sales fell 1% to $3.9 billion but were flat organically, and reported operating income declined 10% to $1.0 billion, down 2% organically, with diluted EPS off 17% to $1.53. The fourth quarter showed the strain most clearly: net sales rose 2% but reported operating income fell 53% to $96 million and EPS dropped to $0.12, weighed by impairment and inventory charges.

The dominant driver was trade politics. The Canadian boycott of American alcohol, tied to U.S. tariff policy, drove a steep decline in Canada sales, and the EU and Canadian provinces have moved to pull American spirits from shelves. As one of the most recognizable American whiskey exports, Jack Daniel's is squarely in the line of retaliatory trade actions, a headwind the company cannot resolve on its own.

The path forward turns on a few variables. Whether the tariff and boycott pressure eases or hardens is the largest, followed by the pace of the spirits-industry destocking normalizing and the durability of demand against weight-loss-drug concerns. Management reaffirmed its outlook through the year despite the disruption, so the near-term test is whether organic trends continue to hold flat while the reported figures recover as one-time charges roll off.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Brown-Forman FY2026 results, June 2026 · Food Dive / Brown-Forman FY2026 commentary

View the full interactive BF-A report on boothcheck